Béta-receptor-blokkolók alkalmazása krónikus szívelégtelenségben

Translated title of the contribution: The use of beta receptor blockers in chronic heart failure

Research output: Contribution to journalArticle

Abstract

The beneficial effects of treatment with beta-blockers in patients with chronic heart failure have been demonstrated in several large, prospective, randomised, placebo-controlled clinical trials. In large trials with mortality as the end-point, the long-term use of bisoprolol, carvedilol, nevibolol and metoprolol succinate have been associated with a reduction In total mortality, cardiovascular mortality, sudden cardiac death and death due to progression of heart failure in patients of functional classes II-IV These favorable clinical experiences warrant a recommendation that beta-blockers should be used in all haemodynamically stable heart failure patients with reduced left ventricular systolic function who are on standard treatment, unless contraindicated. In this review, the most important data of clinical trials and practical considerations of therapy with beta-blockers in heart failure are summarized.

Original languageHungarian
Pages (from-to)463-466
Number of pages4
JournalLege Artis Medicinae
Volume17
Issue number6-7
Publication statusPublished - Jul 2007

Fingerprint

Heart Failure
Mortality
Pragmatic Clinical Trials
Bisoprolol
Metoprolol
Sudden Cardiac Death
Left Ventricular Function
Therapeutics
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Béta-receptor-blokkolók alkalmazása krónikus szívelégtelenségben. / Czuriga, I.

In: Lege Artis Medicinae, Vol. 17, No. 6-7, 07.2007, p. 463-466.

Research output: Contribution to journalArticle

@article{2abc76c141f94399b27fa84e4a3f1b53,
title = "B{\'e}ta-receptor-blokkol{\'o}k alkalmaz{\'a}sa kr{\'o}nikus sz{\'i}vel{\'e}gtelens{\'e}gben",
abstract = "The beneficial effects of treatment with beta-blockers in patients with chronic heart failure have been demonstrated in several large, prospective, randomised, placebo-controlled clinical trials. In large trials with mortality as the end-point, the long-term use of bisoprolol, carvedilol, nevibolol and metoprolol succinate have been associated with a reduction In total mortality, cardiovascular mortality, sudden cardiac death and death due to progression of heart failure in patients of functional classes II-IV These favorable clinical experiences warrant a recommendation that beta-blockers should be used in all haemodynamically stable heart failure patients with reduced left ventricular systolic function who are on standard treatment, unless contraindicated. In this review, the most important data of clinical trials and practical considerations of therapy with beta-blockers in heart failure are summarized.",
keywords = "Beta-blockers, Chronic heart failure, Clinical trials",
author = "I. Czuriga",
year = "2007",
month = "7",
language = "Hungarian",
volume = "17",
pages = "463--466",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - Béta-receptor-blokkolók alkalmazása krónikus szívelégtelenségben

AU - Czuriga, I.

PY - 2007/7

Y1 - 2007/7

N2 - The beneficial effects of treatment with beta-blockers in patients with chronic heart failure have been demonstrated in several large, prospective, randomised, placebo-controlled clinical trials. In large trials with mortality as the end-point, the long-term use of bisoprolol, carvedilol, nevibolol and metoprolol succinate have been associated with a reduction In total mortality, cardiovascular mortality, sudden cardiac death and death due to progression of heart failure in patients of functional classes II-IV These favorable clinical experiences warrant a recommendation that beta-blockers should be used in all haemodynamically stable heart failure patients with reduced left ventricular systolic function who are on standard treatment, unless contraindicated. In this review, the most important data of clinical trials and practical considerations of therapy with beta-blockers in heart failure are summarized.

AB - The beneficial effects of treatment with beta-blockers in patients with chronic heart failure have been demonstrated in several large, prospective, randomised, placebo-controlled clinical trials. In large trials with mortality as the end-point, the long-term use of bisoprolol, carvedilol, nevibolol and metoprolol succinate have been associated with a reduction In total mortality, cardiovascular mortality, sudden cardiac death and death due to progression of heart failure in patients of functional classes II-IV These favorable clinical experiences warrant a recommendation that beta-blockers should be used in all haemodynamically stable heart failure patients with reduced left ventricular systolic function who are on standard treatment, unless contraindicated. In this review, the most important data of clinical trials and practical considerations of therapy with beta-blockers in heart failure are summarized.

KW - Beta-blockers

KW - Chronic heart failure

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=34547181803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547181803&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 463

EP - 466

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -